Singapore, Sept. 30 -- South Korea-based Celltrion has signed an agreement with Eli Lilly to acquire a biopharmaceutical drug substance (DS) manufacturing facility in Branchburg, New Jersey, through its US subsidiary. The move strengthens Celltrion's US manufacturing footprint and eliminates potential tariff-related risks for its products in the US market.

The Branchburg site spans approximately 37 acres and includes four buildings, with 10 acres of vacant land available for future expansion. The acquisition is valued at approximately KRW 460 billion, or about KRW 700 billion when including operational funds.

Celltrion has already implemented a comprehensive US tariff response plan, including transferring two years of inventory to the U...